Among 41 patients with unresectable advanced/metastatic BRAF mutation-positive cutaneous melanoma treated at one of 5 hospitals in 2016-2018, ICIs were the most common 1L treatment (70.7% of regimens) and the most common treatment overall (52.9% across multiple lines of therapy) (53). Here, BRAF is linked to cutaneous melanoma.